Skip to content
Home
Journalists
Headlines
Community
Businesses
Jobs
Learning
Marketplace
Store
(@)
Novo Nordisk sinks after its experimental obesity drug falls short of Eli Lilly’s in head-to-head trial
Earlier this month, Novo predicted that its sales would decline by between 5% and 13% in 2026 amid rising competition.
Author:
J. Edward Moreno
Written by
J. Edward Moreno
in
Business
←
East Coast Blizzard Forces Nationwide Cancellations and Delays
Notorious Mexican Drug Lord Killed, Igniting a Wave of Violence
→
More posts
Protesters, leaders push back against DHS over Newark detention facility conditions
Goldman and Lander spar hard over Israel
Snowflake climbs after Q1 results top expectations, guidance gets a boost
Synopsys drops despite better than expected Q2 results, big boost to full-year guidance
